In last trading session, Cullinan Therapeutics Inc (NASDAQ:CGEM) saw 1.28 million shares changing hands with its beta currently measuring -0.00. Company’s recent per share price level of $28.10 trading at $1.09 or 4.04% at ring of the bell on the day assigns it a market valuation of $1.21B. That closing price of CGEM’s stock is at a discount of -3.63% from its 52-week high price of $29.12 and is indicating a premium of 72.81% from its 52-week low price of $7.64. Taking a look at company’s average trading volume volume of 685.13K if we extend that period to 3-months.
Cullinan Therapeutics Inc (NASDAQ:CGEM) trade information
Upright in the green during last session for gaining 4.04%, in the last five days CGEM remained trading in the green while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $28.10 price level, adding 3.5% to its value on the day. Cullinan Therapeutics Inc’s shares saw a change of 175.76% in year-to-date performance and have moved 48.76% in past 5-day. Cullinan Therapeutics Inc (NASDAQ:CGEM) showed a performance of 65.39% in past 30-days.
Cullinan Therapeutics Inc (CGEM) estimates and forecasts
Statistics highlight that Cullinan Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 223.36% of value to its shares in past 6 months, showing an annual growth rate of 13.01% while that of industry is 12.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 31.00% in the current quarter and calculating -2.40% decrease in the next quarter.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of -$ for the same. And 7 analysts are in estimates of company making revenue of -$ in the next quarter that will end on Jun 2024. Company posted -$ and -$ of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -62.42% during past 5 years.
CGEM Dividends
Cullinan Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
